DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Garassino MC, Martelli O, Broggini M et al.
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Lancet Oncol 2013;
14: 981-988
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.